Insakool-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed for the management of gastrointestinal disorders. Domperidone is a peripheral dopamine D2 receptor antagonist that enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The combination of Domperidone and Rabeprazole in Insakool-DSR Capsule offers synergistic therapeutic benefits by addressing both motility and acid secretion abnormalities, making it suitable for patients experiencing dyspepsia, acid reflux, and other functional gastrointestinal disorders. This medication should be used under medical supervision, with attention to contraindications such as known hypersensitivity to either component, prolactinoma, or severe hepatic impairment. Common adverse effects may include headache, dry mouth, or gastrointestinal disturbances. Insakool-DSR Capsule is typically administered orally, and dosage should be individualized based on clinical response and tolerability.